title: Oral probiotic bacterial administration suppressed allergic responses in an ovalbumin-induced allergy mouse model.
abstract: This study investigated whether orally administered probiotic bacteria (Bifidobacterium bifidum and Lactobacillus casei) and a gram-negative bacterium (Escherichia coli) function as allergic immune modulators to prevent food allergy, according to the hygiene hypothesis. C3H/HeJ mice were sensitized with ovalbumin (OVA) and cholera toxin for 5 weeks. After sensitization, the OVA-induced mice that were not treated with bacteria had significantly increased levels of OVA-specific IgE, total IgE, and IgG1 in sera, as well as scab-covered tails. In comparison, groups treated with B. bifidum BGN4 (BGN4), L. casei 911 (L. casei), or Escherichia coli MC4100 (E. coli) had decreased levels of OVA-specific IgE, total IgE, and IgG1, and decreased levels of mast cell degranulation and tail scabs. OVA-specific IgA levels were decreased in BGN4- and L. casei-treated groups. In conclusion, administration of E. coli, BGN4, or L. casei decreased the OVA-induced allergy response. However, a normal increase in body weight was inhibited in the E. coli-treated mice and in the montreated mice groups during allergy sensitization. Thus, BGN4 and L. casei appear to be useful probiotic bacteria for the prevention of allergy.
authors.affiliation: Department of Food and Nutrition, Seoul National University, San 56-1, Shillim-Dong, Kwanak-Ku, Seoul 151-742, Republic of Korea.
authors.forename: Hyeyoung
authors.initials: H
authors.lastname: Kim
authors.forename: Kubum
authors.initials: K
authors.lastname: Kwack
authors.forename: Dae-Young
authors.initials: DY
authors.lastname: Kim
authors.forename: Geun Eog
authors.initials: GE
authors.lastname: Ji
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001644:Bifidobacterium; D001835:Body Weight; D015550:Cell Degranulation; D002772:Cholera Toxin / Q000276:immunology; D004195:Disease Models, Animal; D004926:Escherichia coli; D005260:Female; D005512:Food Hypersensitivity / Q000209:etiology / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D018928:Immunity, Mucosal; D007071:Immunoglobulin A, Secretory / Q000096:biosynthesis; D007073:Immunoglobulin E / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000097:blood; D007780:Lacticaseibacillus casei; D008407:Mast Cells / Q000276:immunology / Q000502:physiology; D051379:Mice; D008809:Mice, Inbred C3H; D010047:Ovalbumin / Q000276:immunology*; D019936:Probiotics / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D007071:Immunoglobulin A, Secretory; D007074:Immunoglobulin G; D007073:Immunoglobulin E; D010047:Ovalbumin; D002772:Cholera Toxin